Endpoints News 30 may 2026 Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
Endpoints News 29 may 2026 AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya label expansions
Endpoints News 29 may 2026 Agios ends development of tebapivat in low-risk MDS following subpar results
Endpoints News 29 may 2026 David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Endpoints News 29 may 2026 Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
Endpoints News 28 may 2026 #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
Endpoints News 28 may 2026 Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
Endpoints News 28 may 2026 China gene editing startup YolTech raises $70M to move CRISPR therapies forward
Endpoints News 28 may 2026 AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase